The problem is not too much consolidation. Mandating transparency rules could be counterproductive. The worry about spread pricing is beside the point.

We don’t ask companies in other sectors how much they are making on what they bought and sold, says Brian Anderson, MBA, a principal and consulting actuary for Milliman. “I don’t know why we would home in on pharmacy. I feel it’s a forced distraction by somebody not to focus on the real issue, which I feel is utilization, getting people to low-cost generics, looking at low net cost of products and giving people the information to make their own purchasing decisions.”

Managed Healthcare Executive and the Pharmacy Benefit Management Institute (PBMI) have selected Anderson to be recognized as a PBMI Innovator in the program’s inaugural year

See Full Page